Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

29.18 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data
Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments in ovarian, pancreatic, and mCRPC cancers, focusing instead on late-stage... 
Via Benzinga
Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again.
Moderna sustained a rare downgrade on Monday following its guidance cut for the year. 
Via Investor's Business Daily
BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
BioNTech posted a significant Q2 2024 loss of 807.8 million euros. Sales dropped to 128.7 million euros as the demand for COVID-19 vaccines shifted. R&D expenses rose due to late-stage oncology... 
Via Benzinga
Exposures COVID-19
Investing $100,000 in These 7 High-Yield Dividend Stocks Could Generate Over $7,000 in Annual Passive Income
Making passive income should be easy with these great stocks. 
Via The Motley Fool
Is Pfizer Winning Its $43 Billion Bet?
Pfizer's efforts are starting to bear fruit. 
Via The Motley Fool
Pfizer's Options Frenzy: What You Need to Know
Via Benzinga
Pfizer $PFE Beats Earnings Estimates
Pfizer $PFE Beats Earnings Estimates and Raises Full-Year Outlook Amid Cost-Cutting Measures 
Via Chartmill
2 Ultra-High-Yield Dividend Stocks to Buy in August and Hold at Least a Decade
With an average yield above 7% at recent prices, these stocks could give your passive income stream a big boost. 
Via The Motley Fool
Is This Decision by Pfizer Bad News for Eli Lilly?
Lilly's revenue gains have helped its stock to roar higher. 
Via The Motley Fool
Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer
Moderna cuts its 2024 sales forecast due to weaker demand for COVID-19 vaccines. Sales now expected between $3B-$3.5B, down from $4B. Analysts adjust price targets, citing competitive pressures from... 
Via Benzinga
Exposures COVID-19
What Are the Hottest Biotech Stocks Right Now? 3 Top Picks.
Figuring out the hottest biotech stocks can be as simple as looking at the most traded stocks by volume in the last 24 hours. 
Via InvestorPlace
Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review
Apple and Meta had strong results, while AI spending remains robust. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
7 Subdued Blue-Chip Stocks That Will Reward Patient Investors
These are the blue-chip stocks to buy as they represent companies with strong fundamentals and growth acceleration possibility. 
Via InvestorPlace
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.
The popularity surrounding weight loss drugs such as Mounjaro and Ozempic has brought Eli Lilly and Novo Nordisk newfound growth. 
Via The Motley Fool
Bargain-Hunters Paradise: 7 Value Stocks That Are Too Cheap to Ignore
These cheap value stocks are priced right for any bargain hunters seeking deals in the market at the moment. 
Via InvestorPlace
Moderna Slashes Its Outlook On 'Very Low' European Sales Despite Quarterly Beat
Moderna delivered nearly double the sales analysts expected in the second quarter. 
Via Investor's Business Daily
Pfizer Just Confirmed It's a Dividend Investor's Dream Stock
This big pharma stock gives investors juicy and reliable dividends plus the potential for future growth. 
Via The Motley Fool
Pfizer to Buy a GLP-1 Drugmaker? Here's Why You Shouldn't Count on That Happening
Pfizer's debt load could inhibit the company's ability to take on acquisitions in the near term. 
Via The Motley Fool
Pfizer Just Did This for the First Time in 6 Quarters. Time to Buy?
Pfizer shares have advanced 20% over the past three months. 
Via The Motley Fool
The Top 7 Stocks to Buy Now: Summer 2024
Investors should give consideration to taking a position in one of these top stocks to buy that are flashing strong growth signals. 
Via InvestorPlace
Pfizer's Diverse Portfolio And Strong Execution Earn Analyst Praise Despite Patent Concerns
Pfizer reported second-quarter adjusted EPS of $0.60, surpassing the consensus of $0.46. Sales reached $13.28 billion, beating expectations. Analysts highlight Pfizer's robust portfolio, effective... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Pfizer (PFE) Q2 2024 Earnings Call Transcript
PFE earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns. 
Via Benzinga
Tech Stocks Drop Ahead Of Key Earnings; Nvidia Falls, CrowdStrike Hits 8-Month Low: What's Driving Markets Tuesday?
Investor sentiment took a hit on Tuesday as caution prevailed ahead of significant market events, including key tech earnings reports and the Federal Open Market Committee meeting. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Stock Of The Day: Pfizer Pattern Offers Lessons After Better-Than-Expected Q2 Results
Like many things on Wall Street, technical analysis is widely misunderstood. Many analysts try to identify chart patterns without understanding the psychology and price action that creates them. This... 
Via Benzinga
Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer
The market for vaccines and treatments used in managing COVID-19 has shrunk by billions of dollars a year. Forced to rebuild their business, pharmaceutical companies like Pfizer Inc (NYSE: PFE)... 
Via Benzinga
Exposures COVID-19
PFE Stock Earnings: Pfizer Beats EPS, Beats Revenue for Q2 2024
PFE stock results show that Pfizer beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Dow Jumps 200 Points; Pfizer Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
Pfizer Marks First Revenue Growth Since COVID Revenue Peak In 2022, Lifts Annual Guidance
Pfizer reports Q2 adjusted EPS of $0.60, beating the $0.46 consensus. Sales reached $13.28 billion, driven by acquired products and new launches, despite a decline in Comirnaty. Updated 2024 revenue... 
Via Benzinga
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.